RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

J Natl Cancer Inst. 2022 Mar 8;114(3):475-476. doi: 10.1093/jnci/djab159.

Authors

Ashley M Hopkins¹, Ganessan Kichenadasse^{1

2}, Jessica M Logan³, Andrew Rowland¹, Michael J Sorich¹

Affiliations

¹ College of Medicine and Public Health, Flinders University, Adelaide, Australia.
² Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Adelaide, Australia.
³ Clinical and Health Sciences, University of South Australia, Adelaide, Australia.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Immune Checkpoint Inhibitors
Lung Neoplasms* / pathology
Smoking / adverse effects
Tobacco Smoking

Substances

Immune Checkpoint Inhibitors